Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NVyxcWk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3lOeKh|ryP NHvLe4s1QMLiaB?= M2LOToJtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>? M3XlVlI3OzVyNU[1
NP69 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HmcGlEPTB;M{GuOlnDuTJwNUSg{txO MYmyOlI2OjV5NR?=
NP460 NF;IU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S5XGlEPTB;MkKuPFXDuTFwMUig{txO MXWyOlI2OjV5NR?=
C666-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHIRWlVUUN3ME2xPU46PcLzOD65N{DPxE1? M4DPSVI3OjV{NUe1
C666-1 NGO1SXNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGPnZ2oyOCEEtV2= M2DGVlQ5KGh? NV3KPXNtTE2VTx?= NF;ISYh{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDjbZNxdGG2aX6= MoX5NlYzPTJ3N{W=
C666-1  NWTLcIl2TnWwY4Tpc44hSXO|YYm= MWWxNEDDvU1? MkfwNlQhcA>? MV\EUXNQ MVLhZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> M3flVFI3OjV{NUe1
C666-1 Mmn5RZBweHSxc3nzJGF{e2G7 MY[xNEDDvU1? M3\lNFQ5Nzd{IHi= NEC3VIVFVVOR M1TOfZNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NXXSUYpGOjZ{NUK1O|U>
A549 NWfrbG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\FeZVnOjRiaB?= NWCx[JRjUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= NYXyUlFjOjZzMkWyN|A>
A549-NTC M1fXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCyOEBp NInMV3VKSzVyPUG5MlQzKMLzIEGuPVYh|ryP NFiyNlAzPjF{NUKzNC=>
A549-920 NFHyflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\DOFI1KGh? NFLIZ3ZKSzVyPUOzMlg2KMLzIESuPFQh|ryP M4fHVFI3OTJ3MkOw
CRL-5908 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYeyOEBp NF2z[mNKSzVyPUO4MlcyKMLzIEKuOFMh|ryP MXyyOlEzPTJ|MB?=
L6 NE\oclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13BNVExyqEQvF5CpC=> NWLNcYpoOjRxNEivO|IhcA>? NX70V2JXTE2VTx?= M4DGR4lvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? MVqyOVg4OTd7NB?=
C2C12 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGxNOKh|ryPwrC= MXKyOE81QC95MjDo MoTXSG1UVw>? NE\PWVFqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? MXSyOVg4OTd7NB?=
MCF-7  M2jIeGZ2dmO2aX;uJGF{e2G7 MnfaNVDDqM7:TR?= NV\SeWFMTE2VTx?= NIf6fnVqdmirYnn0d{BkgWOuaX6gSFEh[W6mIFTpZ4VzyqB? M4nnNVI2PzB{N{Cz
DU4475  NXG5OXhiTnWwY4Tpc44hSXO|YYm= NIH1Umc2NzFyL{KwJO69VQ>? NHS1Z2szPMLiaB?= MUnkc5dvemWpdXzheIV{KFSxY3GtNUBld3OnIHTldIVv\GWwdHz5 M{XtblI2PTR5MUe0
SMMC-7721 M{HHRmZ2dmO2aX;uJGF{e2G7 NFvmd5kyOCEQvF2= M2HrSFQ5KGh? MXPEUXNQ MYHjZZV{\XNiRF7BJGRUSiCmYX3h[4U> NHH3S4YzPTV2NEO2NS=>
SMMC-7721 MVLGeY5kfGmxbjDBd5NigQ>? NVjPdVVZOTBizszN NUT1doJ6PDhiaB?= MVvEUXNQ NVroPXppcW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? NF7qcmczPTV2NEO2NS=>
SMMC-7721 MnK4SpVv[3Srb36gRZN{[Xl? NFG2bXYyOCEQvF2= NFLue2I1QCCq MWfEUXNQ M4ThVolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZtMgTWZPSjIEoH3SUmE> NV60Z5pwOjV3NESzOlE>
SMMC-7721 NX3wOnZoTnWwY4Tpc44hSXO|YYm= MUixNEDPxE1? Mlj0N|YhcA>? MoDwSG1UVw>? NUjkWZJK[2G3c3XzJJRp\SCnY4TvdIlkKGW6cILld5Nqd25ib3[gTWZKOTZ? MlP1NlU2PDR|NkG=
MCF-7 M2nFS2Z2dmO2aX;uJGF{e2G7 MkS2NVDDqM7:TR?= NELxZ|IxNTJ2IHi= NXHjWpdIcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx M2HT[VI2PDh{M{ez
OVCAR10 NEjWZnBHfW6ldHnvckBCe3OjeR?= MmjVNVDDqM7:TR?= MX6yNYjDqA>? NYDETJc1TE2VTx?= MWTpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MU[yOVQzPjV2OB?=
NCI-H23 M37pWmZ2dmO2aX;uJGF{e2G7 NF;0OpUyOMLizszN NFLoe|MzOWkEoB?= NXnHR|lDTE2VTx?= MYXpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MVKyOVQzPjV2OB?=
A2780 NXji[HA4TnWwY4Tpc44hSXO|YYm= MYGxNOKh|ryP NVLRUYF6OjGqwrC= NYfXRnFNTE2VTx?= Mn;vbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> NYjHR3BXOjV2Mk[1OFg>
NCI-H23 MofGSpVv[3Srb36gRZN{[Xl? MW[xNOKh|ryP NI\yW2QzOWkEoB?= NGLSXIVFVVOR MkHV[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= MYqyOVQzPjV2OB?=
A2780 MoLYSpVv[3Srb36gRZN{[Xl? NFfKO3UyOMLizszN MlPLNlFpyqB? MYPEUXNQ NX75ZmtK\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> NVLofHpUOjV2Mk[1OFg>
HCT116  NF3lWGRHfW6ldHnvckBCe3OjeR?= MnXsNVAhyrWP MnnxNlQhcA>? NVfyV3Vo[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 NIfQVY8zPTN6MEC1OS=>
MCF-10CA1a NWTtZ3d5TnWwY4Tpc44hSXO|YYm= MUCxNOKh|ryP MXO0PEBp NF3xfXpFVVOR NX3ZeZlxcW6qaXLpeJMh[mG|YXygbY53[XOrb36gZY5lKHKnZIXj[YQhXEeILd8yN{1qdmS3Y3XkJIlvfmG|aX;uJJRwKGKjc3HsJIxmfmWucx?= MVeyOVI2Pzd{OR?=
MCF-10A1  M1j4TGZ2dmO2aX;uJGF{e2G7 M1jJc|ExyqEQvF2= MUKyOE81QCCq M4LlVWROW09? NYK3UY03cW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi NIC3Z5ozPTJ3N{eyPS=>
MCF-10CA1a M4\LS2Z2dmO2aX;uJGF{e2G7 NEnwNoMyOMLizszN NWThZlZ3OjRiaB?= NYrR[G1kTE2VTx?= NIfwfIZl\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= NVi5O4V1OjV{NUe3Nlk>
MCF-10CA1a MWHGeY5kfGmxbjDBd5NigQ>? NX3wNlI5OTEEoN88US=> MkjBNlQhcA>? M4jyTmROW09? MnG1bY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M{D0VVI2OjV5N{K5
SK-BR-7 NIDmZ2NHfW6ldHnvckBCe3OjeR?= NWrwWXpFOTEEoN88US=> MnHXNlQhcA>? MYDEUXNQ MVHpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? Ml74NlUzPTd5Mkm=
SUM102PT MnizSpVv[3Srb36gRZN{[Xl? M{S3SVExyqEQvF2= NUDOO|dMOjRiaB?= MlvISG1UVw>? M4rhOYlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MoTUNlUzPTd5Mkm=
RAW 264.7 MVfGeY5kfGmxbjDBd5NigQ>? MlzDNVDDqM7:TR?= M33YcFMxKG2rbh?= NHP3TVRxemW4ZX70d{B1cGVicEWzJJJm\HWldHnvckBqdiC{ZYPwc45{\SC2bzDMVHM> M3K1NFI2OTd{NUS3
RAW 264.7 NVLEVHh3TnWwY4Tpc44hSXO|YYm= M1ewSFExyqEQvF2= MWizNEBucW5? MkLTdoVlfWOnczD0bIUhVFCVLXH1[41mdnSnZDD0bIUhVkZvzsrCJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhZ5Rqfmm2eR?= NXrHR4ZzOjVzN{K1OFc>
RAW 264.7 MXnGeY5kfGmxbjDBd5NigQ>? NYi3[FZXOTEEoN88US=> NIe5XGU{OCCvaX6= NVPtRYhXcW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh MkTRNlUyPzJ3NEe=
MCF7  NUTiWotqS2WubDDWbYFjcWyrdImgRZN{[Xl? MW[yMlUhyrWP MYq1JIQ> MnTkSG1UVw>? M{fze5NmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= NVfEZ5huOjVyOEW5NFI>
MCF7  NWHmdolvTnWwY4Tpc44hSXO|YYm= M{\rRVIvPSEEtV2= M4rzc|Q5KGh? M3LDO2ROW09? NWHXcoVY\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? MXWyOVA5PTlyMh?=
ACHN M3;tOmNmdGxiVnnhZoltcXS7IFHzd4F6 MoPFNE42NTFyIN88US=> NHjidYYxNTZiZB?= MUXEUXNQ MkfMbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4rVN|I2ODZ5N{i3
Caki-2 M3;tSWNmdGxiVnnhZoltcXS7IFHzd4F6 MXGwMlUuOTBizszN MVewMVYh\A>? M4DDOmROW09? M1PaWolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVuyOVA3Pzd6Nx?=
A498 MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHjNVXMxNjVvMUCg{txO NEDjRVgxNTZiZB?= MVnEUXNQ NXzaRVROcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVWyOVA3Pzd6Nx?=
115 M1[wV2NmdGxiVnnhZoltcXS7IFHzd4F6 M2LxXFAvPS1zMDFOwG0> MXywMVYh\A>? NEPNPFdFVVOR MlP6bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2D2dVI2ODZ5N{i3
117 M1ftdmNmdGxiVnnhZoltcXS7IFHzd4F6 NF7lO5kxNjVvMUCg{txO MmTVNE03KGR? MYXEUXNQ NH3vfohqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1Lmc|I2ODZ5N{i3
ACHN NUK1cmRGTnWwY4Tpc44hSXO|YYm= M1HWeVAvPS9zL{Wg{txO NVXXOo9OPDhiaB?= NFHUcG9FVVOR M1nJXIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NXXtdW5DOjVyNke3PFc>
Caki-2 NUnV[FRFTnWwY4Tpc44hSXO|YYm= M2XxWlAvPS9zL{Wg{txO NUPH[3hUPDhiaB?= M17iZWROW09? NEXuVINt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NHm1cZIzPTB4N{e4Oy=>
A498 MY\GeY5kfGmxbjDBd5NigQ>? M3TGOFAvPS9zL{Wg{txO M3TlfVQ5KGh? NGXkXnJFVVOR MVjs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? M4LmWlI2ODZ5N{i3
115 MXnGeY5kfGmxbjDBd5NigQ>? M37aXlAvPS9zL{Wg{txO NIm5VZU1QCCq NEjWfldFVVOR MX;s[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NInqfJczPTB4N{e4Oy=>
ACHN NI\4PGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVi1JO69VQ>? NUfvbmVFPDhiaB?= M4Xv[2ROW09? MVzpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= MU[yOVA3Pzd6Nx?=
Caki-2 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCySVNRPSEQvF2= MXy0PEBp NHTNdXpFVVOR M{XjcIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NFzESm4zPTB4N{e4Oy=>
A498 NVPQO49xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jDcFUh|ryP MnftOFghcA>? MXLEUXNQ M2WxTolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NWjFPVF[OjVyNke3PFc>
115 M{DES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK1JO69VQ>? NFjE[|U1QCCq M13QVmROW09? NVe0SHBLcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MVuyOVA3Pzd6Nx?=
ACHN Moj3SpVv[3Srb36gRZN{[Xl? M{mwZ|Uh|ryP NWLxPI4xPDhiaB?= NWrIUWNxTE2VTx?= NU\xfodEcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NX62V2I5OjVyNke3PFc>
Caki-2 MYPGeY5kfGmxbjDBd5NigQ>? M4DJbFUh|ryP MlXiOFghcA>? MV;EUXNQ NHuyXpdqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NYjZOY9bOjVyNke3PFc>
A498 Mn7vSpVv[3Srb36gRZN{[Xl? Ml60OUDPxE1? M2\afFQ5KGh? MnK3SG1UVw>? MVnpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NXTldXBzOjVyNke3PFc>
115 NUix[5d5TnWwY4Tpc44hSXO|YYm= NGmw[4Q2KM7:TR?= NIjF[Wo1QCCq NFe1cmxFVVOR MVHpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MlfHNlUxPjd5OEe=
MOLM-13 M3zLcWZ2dmO2aX;uJGF{e2G7 M{e3cFbDqM7:TR?= NGTqXW8xNThiaB?= NFyzSHVFVVOR Mn\HbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ MUeyOFg5PTB6Mh?=
MOLM-13 NIPZRYFHfW6ldHnvckBCe3OjeR?= MVG2xsDPxE1? M3j4OVYhcA>? MYHEUXNQ MV7lcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly MVSyOFg5PTB6Mh?=
HepG2 M{TPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfP[XJvPzJiaB?= NX7iN2JqTE2VTx?= NH\aVolKSzVyPUO1Mlg3KMLzIEKuPUDPxE1? NFHv[5kzPDh6NEiwPS=>
HepG2/As MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO3NkBp MoDZSG1UVw>? MW\JR|UxRTZ6LkGzJOKyKDlwNjFOwG0> M{\4XFI1QDh2OEC5
SMMC7721 M2e1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS3NkBp MnrZSG1UVw>? NWnWO29HUUN3ME2zNU4zQCEEsTC0MlIh|ryP M17yU|I1QDh2OEC5
SMMC7721/Ac M3fhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj6O|IhcA>? NET2SXpFVVOR MUnJR|UxRTV3LkKxJOKyKDVwMEOg{txO MlrCNlQ5QDR6MEm=
Huh-7 M1\0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWi3NkBp NGPvenlFVVOR NVizRnZUUUN3ME2zN{46PiEEsTCzMlkh|ryP NHjvSFAzPDh6NEiwPS=>
Hep3B Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm3NkBp M3;PSmROW09? M1XaXGlEPTB;MkCuNVghyrFiMT64OEDPxE1? NXXPWGhQOjR6OES4NFk>
HepG2 M{fsNWFxd3C2b4Ppd{BCe3OjeR?= NV3RXZlUcW6mdXPld{BieG:ydH;zbZM> NH\XeXgzPDh6NEiwPS=>
SMMC7721 NEm3fnBCeG:ydH;zbZMhSXO|YYm= NUH1Vno6cW6mdXPld{BieG:ydH;zbZM> MoTLNlQ5QDR6MEm=
Huh-7 MlnJRZBweHSxc3nzJGF{e2G7 M1L0dIlv\HWlZYOgZZBweHSxc3nz NGnPZlQzPDh6NEiwPS=>
Hep3B NFPkRodCeG:ydH;zbZMhSXO|YYm= M3rEUIlv\HWlZYOgZZBweHSxc3nz NXLZNGVNOjR6OES4NFk>
U2OS  NFTDdGNHfW6ldHnvckBCe3OjeR?= NHL5WIMzOCEQvF2= M2DGR|I1KGh? NFiwfVJqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCEQ1yyRVEtKEKFTGjMxsBidmSEQ1zX NIfNNIEzPDh4N{K1PS=>
AML2 MoW5RZBweHSxc3nzJGF{e2G7 NGLHVpQzNzFyIN88US=> NGnFTIkzPC92ODDo MVzpcoR2[2W|IHHwc5B1d3Orcx?= NXPP[WNmOjR4NUm3OFk>
MOML13 NUjybFRUSXCxcITvd4l{KEG|c3H5 MYqyM|ExKM7:TR?= MYSyOE81QCCq NWnFSFR2cW6mdXPld{BieG:ydH;zbZM> MmrXNlQ3PTl5NEm=
AML2 NXXaWHh3TnWwY4Tpc44hSXO|YYm= M3zpclEx|ryP NY[zT4IyOi92IHi= NVj0XIdqcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> MVeyOFY2QTd2OR?=
AML3 MojZSpVv[3Srb36gRZN{[Xl? Ml7jNVDPxE1? NEXRPVIzNzRiaB?= MWrpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= MofpNlQ3PTl5NEm=
MOML13 NGLL[pdHfW6ldHnvckBCe3OjeR?= NEHRNncyOM7:TR?= NFXoNoQzNzRiaB?= MYjpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= MUmyOFY2QTd2OR?=
BeWo NVnBdIZkTnWwY4Tpc44hSXO|YYm= NVfEZ3c5OzBiwsXN MUSyOEBp MWLpcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= MWqyOFQ6QDF3NB?=
BeWo M{TZbWFxd3C2b4Ppd{BCe3OjeR?= NE[1ToU{OCEEtV2= NXW0S5U5OjRiaB?= MoTlbY5kemWjc3XzJIFxd3C2b4Ppdy=> NUHI[lFrOjR2OUixOVQ>
OCI M1;FfmZ2dmO2aX;uJGF{e2G7 NIfxWGEyOCEQvF2= MnnONlQhcA>? MnqweZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w M3HkUVI1PDd|NU[y
MOLM M3PlNmZ2dmO2aX;uJGF{e2G7 M376dVExKM7:TR?= MkTyNlQhcA>? NIDySWt2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= NEDiTFczPDR5M{W2Ni=>
U2OS  NVm1OXBjTnWwY4Tpc44hSXO|YYm= M3TG[lIxKM7:TR?= NF3PXVYzPCCq M{TEVolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? M3HZ[FI1OzZ4MEC3
RKO Mme1SpVv[3Srb36gRZN{[Xl? MVWyNEDPxE1? NGLP[IwzPCCq M2jYW4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? NUnEZmd7OjR|Nk[wNFc>
U2OS  MlfXSpVv[3Srb36gRZN{[Xl? MnPWNlAh|ryP NYjIXWNWOjRiaB?= MnXFbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MYGyOFM3PjByNx?=
RKO M2TkdmZ2dmO2aX;uJGF{e2G7 MkD3NlAh|ryP NYm0PYQ5OjRiaB?= MlLubY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= NGKxZ|QzPDN4NkCwOy=>
SMMC-7721  MmrNR4VtdCCYaXHibYxqfHliQYPzZZk> NH;wSWYyNjJ3LUKwJO69VQ>? Mkf5NlQwPDhxN{KgbC=> MX3EUXNQ MmX2bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NFHPeG4zPDJ6NkOxNi=>
HuH-7 NXG4UYJ6S2WubDDWbYFjcWyrdImgRZN{[Xl? NViyNIlPOS5{NT2yNEDPxE1? NVTxUYNFOjRxNEivO|IhcA>? M2m0TmROW09? MYPpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NVW4OFlYOjR{OE[zNVI>
SMMC-7721  NGfLPYNCeG:ydH;zbZMhSXO|YYm= NXTJ[o5MOjBizszN M4TIXVQ5KGh? NIO0PGVFVVOR MVvpcoR2[2W|IHHwc5B1d3Orcx?= MmDPNlQzQDZ|MUK=
HuH-7 NUPWeJhMSXCxcITvd4l{KEG|c3H5 MV2yNEDPxE1? M3PJOFQ5KGh? NWO5[YdZTE2VTx?= M{[zUIlv\HWlZYOgZZBweHSxc3nz M{[2PFI1Ojh4M{Gy
SMMC-7721  NInvXY9HfW6ldHnvckBCe3OjeR?= MkDhNVAh|ryP NVnWb2pKOzZiaB?= MW\EUXNQ NH\FZ5dld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? NHjPOXQzPDJ6NkOxNi=>
HuH-7 MVjGeY5kfGmxbjDBd5NigQ>? M{SwelExKM7:TR?= MV6zOkBp NUDVe4tYTE2VTx?= M3;NUoRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ NU\0PYdEOjR{OE[zNVI>
AT2 NVS4U|k5TnWwY4Tpc44hSXO|YYm= MlXzOU8yOCEQvF2= MmntcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? MnHoNlQzPDB{MEO=
REH NFv4dIRHfW6ldHnvckBCe3OjeR?= M2XMXlUwOTBizszN Mmf0cIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? MYiyOFI1ODJyMx?=
UoCB6 NYX5OW15TnWwY4Tpc44hSXO|YYm= MYW1M|ExKM7:TR?= M1ywXIxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li MlTxNlQzPDB{MEO=
AT2 MkTDR4VtdCCYaXHibYxqfHliQYPzZZk> NGHVUYUxNTJ3IN88US=> M1fOPIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NWDVTZRxOjR{NECyNFM>
REH M{izeWNmdGxiVnnhZoltcXS7IFHzd4F6 NHrW[JoxNTJ3IN88US=> NVnTVGhVcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MWKyOFI1ODJyMx?=
UoCB6 NEPOOWhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3zYd|AuOjVizszN NFHtUHRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYf5[ppPOjR{NECyNFM>
A2780 M{[xe2Z2dmO2aX;uJGF{e2G7 MnrHOU8yOC9{MDFOwG0> MYSyOEBp NXTiSZQ1fXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= M13SdlI1OTN4MUS3
H460 NFLOdndHfW6ldHnvckBCe3OjeR?= MmHJOU8yOC9{MDFOwG0> NXT1VYZUOjRiaB?= M4ftUZVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NYTGRWhWOjRzM{[xOFc>
Lovo  NFHXTXdHfW6ldHnvckBCe3OjeR?= NX7qc2tXPS9zMD:yNEDPxE1? MoG1NlQhcA>? NYG2boNtfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= M4m5blI1OTN4MUS3
A2780 MV3BdI9xfG:|aYOgRZN{[Xl? NYHaV5NIPS9zMD:yNEDPxE1? NXX6PWNMOjRiaB?= M2PzRoVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MmHlNlQyOzZzNEe=
H460 MV\BdI9xfG:|aYOgRZN{[Xl? NV64VXpJPS9zMD:yNEDPxE1? NFWxOIkzPCCq MkLY[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> MXyyOFE{PjF2Nx?=
Lovo  M3vOOmFxd3C2b4Ppd{BCe3OjeR?= NFrZbJE2NzFyL{KwJO69VQ>? M3O5WVI1KGh? MVnlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MXWyOFE{PjF2Nx?=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID